1-4 of 4
Ephraim Fuchs, MD
Close
Sort by
Journal Articles

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Heather Symons, MD, MHS, Allen R. Chen, MD, PhD, MHS, M. Sue Leffell, PhD, Marianna Zahurak, M.S., Kathy Schultz, Heather Karaszkiewicz, Leo Luznik, MD, Javier Bolanos Meade, MD, Yvette L. Kasamon, MD, Lode J. Swinnen, MD, Douglas Edward Gladstone, MD, Richard J. Jones, MD, Ephraim Fuchs, MD, MBA
Journal: Blood
Blood (2010) 116 (21): 2362.
https://doi.org/10.1182/blood.V116.21.2362.2362
Published: 2010
Journal Articles

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Amy E. DeZern, MD, Anthony Sung, MD, Sharon Kim, MD, Hua-Ling Tsai, MS, Jeanne Kowalski, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Steven D. Gore, M.D., Ephraim Fuchs, MD, Michael A McDevitt, MD, PhD, Leo Luznik, MD, Richard J. Jones, MD, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2172.
https://doi.org/10.1182/blood.V116.21.2172.2172
Published: 2010
Journal Articles

Critical Role of CD4+Foxp3+ T Cells In Gvhd Prevention with High-Dose Posttransplant Cyclophosphamide (Cy).

Sudipto Ganguly, PhD, Ephraim Fuchs, MD, Vedran Radojcic, MD, Leo Luznik, MD
Journal: Blood
Blood (2010) 116 (21): 3749.
https://doi.org/10.1182/blood.V116.21.3749.3749
Published: 2010
Journal Articles

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Paul O’Donnell, MD, PhD, Leo Luznik, MD, Heather Symons, MD, Richard Jones, MD, Ted Gooley, PhD, Elizabeth Harrington, MSN, Sandra Warnock, Brenda Sandmaier, MD, Rainer Storb, MD, Ephraim Fuchs, MD
Journal: Blood
Blood (2006) 108 (11): 3135.
https://doi.org/10.1182/blood.V108.11.3135.3135
Published: 2006